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Ovarian cancer is the most lethal gynecologic malignancy in the world. The origin or the pathogenesis of
epithelial ovarian cancer is poorly understood, which often leads to failure of early detection. Devel-
opment of a new approach to reduce mortality is urgent. The fallopian tubes were once seen as an
extremely rare site for cancer, but increasing evidence now suggests that they could be involved in
initiation of the most aggressive ovarian carcinoma. As a result of evolution to prevent ectopic pregnancy,
not only is the fallopian tube “poor soil” for carcinogenesis, but angiogenesis is also inhibited there.
However, every cycle of ovulation results in changes in which tubal epithelial cells are dislodged and
implanted on the denuded surface of the ovary, resulting in the formation of an inclusion cyst. This is the
very beginning of serous ovarian carcinogenesis. To prevent ovarian cancer, a salpingectomy might be
recommended during hysterectomy because this procedure can effectively reduce the incidence of
ovarian cancer. Application of these new concepts will allow for a more rational approach to screening,
treatment, and prevention, which could potentially have a signiﬁcant impact in reducing mortality from
this devastating disease.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Ovarian cancer is the second most common gynecologic ma-
lignancy and the most common cause of gynecologic cancer death
in developed countries [1]. Ovarian cancer is often diagnosed when
the disease has spread, making it more difﬁcult to treat. This poor
prognosis has remained a major issue for the last 50 years. It was
previously believed that 95% of ovarian malignancies were derived
from epithelial cells, but it is now though that this concept is false
according to numerous recent morphologic and molecular genetic
studies. Epithelial ovarian cancer (EOC) has various histological
types, including serous, mucinous, endometroid, transitional cell,
and clear cell types. The question of why the epithelium of the
ovary (mesothelium) can develop into tumors of different histo-
logical types has led to the proposal that ovarian cancer develops
anew [2]. The subsequent question is where these cancer cells
come from.s and Gynecology, Buddhist
ang Road, Hualien Taiwan.
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ddhist Compassion Relief Tzu ChiKurman and colleagues divided ovarian tumors into two groups
designated type I and type II [3]. Type I tumors are slowgrowing and
are generally conﬁned to the ovary on diagnosis. They develop from
well-established precursor lesions, including low-grade micro-
papillary serous carcinoma, and mucinous, endometrioid, and clear
cell carcinomas. By contrast, type II tumors are rapidly growing and
highly aggressive neoplasms without well-deﬁned precursor le-
sions. Type II tumors include high-grade serous carcinoma, malig-
nant mixed mesodermal tumors (carcinosarcomas), and
undifferentiated carcinomas. This groupof tumorshas ahigh level of
genetic instability and is characterized by mutation of TP53. Recent
studies have shown strong evidence suggesting that what we
thoughtwereprimaryovarian tumors in the past actually originated
from other pelvic organs. It has been proposed that serous tumors
arise from implantation of epithelium from the fallopian tube [4].
As a result of evolution to prevent ectopic pregnancy, not only is
the fallopian tube “poor soil” for carcinogenesis, but angiogenesis is
also inhibited there, which suggests why fallopian tube cancer is
rare. By contrast, the ovary is “nourished soil”, rich in blood supply
and suitable for the survival of imported cells. This review article
reports recent research ﬁndings on the cells of origin and patho-
genesis in EOC. In addition, prevention methods such as prophy-
lactic salpingectomy are discussed.Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
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and ovulation on EOC
To prevent ovarian cancer, tubal ligation was recommended for
carriers of BRCA1 or BRCA2 mutations who have undergone child-
birth [5]. Moreover, salpingectomy is strongly recommended by
experts for women opting for tubal ligation [6]. A recent meta-
analysis of 30 studies on correlation between tubal ligation and
risk of ovarian cancer demonstrated a signiﬁcant inverse associa-
tion [7]. There is an approximately 26e30% decrease in ovarian
cancer for womenwho have had a tubal ligation compared to those
who have not had the procedure. In secondary analyses in the same
study, the ovarian cancer risk was higher for endometrioid tumors
(relative risk 0.45, 95% conﬁdence interval 0.33e0.61) compared
with serous tumors. This implies that the cells of origin for ovarian
cancer travel to the ovary via the fallopian tubes. Functional or
structural disorders of the fallopian tube cannot prevent retrograde
movement of the cells of origin, so the fallopian tubes act as an
“accomplice” in ovarian carcinogenesis.
According to numerous observational epidemiologic studies,
ovulation plays a pivotal role in the very beginning of EOC patho-
genesis. Both early menarche and late menopause have been
associatedwith increased risk of EOC [8,9]. Womenwho have never
gone through pregnancy seem to have an increased risk of EOC [10].
A decreased risk of EOC has been associated with womenwho have
had a full-term pregnancy [10e12]. A higher ovarian cancer risk is
also seen in women who are infertile [13,14] and in women who
have endometriosis or polycystic ovarian syndrome. These studies
demonstrate a signiﬁcant positive correlation between the total
number of ovulations and the risk of EOC: the higher the number of
ovulations, the greater the risk of EOC.3. Most EOC does not originate from the ovary
The theory of ovarian carcinogenesis has long been debated. The
traditional view suggests that the cells of origin for different ma-
lignant ovarian tumors all arise from ovarian surface epithelium
and subsequent metaplastic changes lead to various cancer cell
types. In the embryonic development of the human reproductive
system, the Müllerian ducts (or paramesonephric ducts) develop
into the upper vagina, cervix, uterus, and fallopian tubes in females.
The ovaries develop frommesodermal epithelium on the urogenital
ridges separate from the Müllerian ducts. Therefore, it is quite
unreasonable that ovarian cancer would have different cell types.
Thus, it has been proposed that serous tumors arise from implan-
tation of epithelium from the fallopian tube. It is assumed that
endometrioid and clear cell tumors are related to endometriosis,Fig. 1. Histologic and molecular evidence shows that ovarian cancer originated from the fall
in the lumen of the left fallopian tube (40, hematoxylin and eosin staining). (B) Serous car
tube cancer (brown color, 100).which develops from endometrial tissue by retrograde menstrua-
tion. Thus, endometriosis is regarded as the precursor of endome-
trioid and clear cell tumors [4].4. Histological and molecular evidence
Serous tubal intraepithelial carcinoma (STIC) is the earliest
morphologically recognizable form of tubal high-grade serous car-
cinoma (Fig. 1). These precancerous or cancerous lesions in the fal-
lopian tubes have long been ignored by pathologists. During the last
few years, there has been a dramatic shift in attention to STIC. It is
now considered the precursor of serous ovarian or peritoneal carci-
noma [15,16]. It is particularly interesting that at leasthalf of papillary
serous peritoneal carcinoma cases are associated with STIC [16].
These tumors always exhibit abnormal immunohistochemical
expressionofp53 [17]. Thep53 signaturehas recently beendescribed
andproposed as a precursor of STIC (Fig.1). It can be characterized by
p53 overexpression and lowKi-67 labeling. One study demonstrated
that57%ofp53 signatures contain a TP53mutation,which is themost
common gene mutation found in ovarian cancer [15].
High similarity in morphology and gene expression between
fallopian tube epithelium and serous borderline ovarian tumors
(SBT) further indicates the close relation between these two organs
[18]. Both ciliated and secretory cells are found in SBT, similar to the
fallopian tube epithelium. Paired box 2 (PAX2) is expressed
throughout the female genital tract, particularly in secretory cells of
the fallopian tube epithelium. Secretory cell outgrowths (SCOUTs)
exist in thewhole length of the fallopian tube. SCOUTs lacking PAX2
expression have been observed in benign fallopian tubes and are
more common in the fallopian tubes of patients with SBT or high-
grade serous cancer [19,20]. These ﬁndings do not deﬁnitively
establish that SBT is derived directly from SCOUT, but there must be
a relationship between these organs.
Another recent gynecological pathology study demonstrated
that gene expression proﬁles of tubal and ovarian serous carcinoma
are similar. p53 was highly expressed but PAX2 and phosphatase
and tensin homolog (PTEN) expression was markedly reduced or
absent in high-grade endometrioid and serous carcinomas of the
ovary and in fallopian tubes [21]. These ﬁndings led to the
conclusion that high-grade ﬁmbrialeovarian carcinomas all have
altered p53, PTEN, and PAX2 regulation.
Dicer, an essential gene for microRNA synthesis and PTEN, is a
key negative regulator of the phosphoinositol 3-kinas (PI3K)
pathway. These genes related to fallopian tube cancer are also up- or
down-regulated in human serous ovarian cancers, as mentioned
above. DicerePten double-knockout mice were successfully used to
show that high-grade serous carcinomas arise from the fallopianopian tube epithelium in this case. (A) Serous fallopian tube carcinoma (CA) was found
cinoma of the ovary (200). (C) Immunohistochemical stain for p53 over the fallopian
M.-K. Hong et al. / Tzu Chi Medical Journal 25 (2013) 203e205 205tube [22]. Primary fallopian tube tumors spread to engulf the ovary
and then aggressively metastasized throughout the abdominal
cavity, causing ascites and killing 100% of the mice. After removal of
the fallopian tube at an early age there was no cancer formation,
implying that the fallopian tube is the origin of ovarian cancer.
Interestingly, primary carcinomas were ﬁrst observed in the stroma
of the fallopian tube, suggesting that these epithelial cancers have a
mesenchymal origin. Thus, this mousemodel represents a paradigm
for the origin and initiation of high-grade serous ovarian cancer [22].5. Prevention: performing salpingectomy during pelvic
surgery
Given the obstacles in early detection (screening) and the sig-
niﬁcant but relatively limited success in treatment, attention
should be directed to primary prevention. This takes on particular
relevance with the recognition that the majority of ovarian carci-
nomas are derived from cells in the fallopian tube or from passage
of endometrial tissue through the fallopian tubes, and the impor-
tant role of ovulation in ovarian carcinogenesis. Salpingectomy
alone may be sufﬁcient to accomplish this, because removal of the
fallopian tubes would reduce the risk of ovarian cancer while
preserving ovarian function [23].
Any method that can reduce ovulation or prevent the passage of
cells of “foreign origin” to the ovary or peritoneum should be
encouraged, such as increased gravidity, breastfeeding, and routine
bilateral salpingectomy or ﬁmbriectomy during a hysterectomy.
Instead of tubal ligation, bilateral salpingectomy is suggested to
prevent this devastatingcancer, even if awoman isnot athigh risk for
ovarian cancer [6e9].Moreover, topreventprematureovarian failure
caused by salpingectomy, the procedure should be performed care-
fully. The vessels supplying the fallopian tube include branches from
the ovarian or uterine artery, which form arcades at themesosalpinx
andmeso-ovary while also supplying the ovary. Therefore, complete
excisionof the tubes shouldbe carriedoutwith caution, startingwith
themesosalpinx at the ﬁmbrial end and performing ligation close to
the fallopian tube as far as possible from the ovary. Ovarian blood
ﬂow and function can be preserved using this approach.6. Conclusion
The fallopian tube is undoubtedly the site of origin of EOC. The
fallopian tube also acts as a conduit, connecting the lower genital
tract to the peritoneal cavity. Functional disorders of the fallopian
tubes may even enhance retrograde endometrium or cervical cells,
facilitating factors that induce local inﬂammation. Salpingectomy
can reduce the incidence of ovarian cancer. All female patients
should be given this information before receiving pelvic surgery and
the patient herself should make the best treatment choice. Other
approaches such as oral medication should also be explored based
on these new insights into ovarian carcinogenesis. New diagnostic,
prevention and therapeutic approaches should be developed based
on our evolving understanding of ovarian carcinogenesis.Acknowledgments
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